REFERENCES
1. Vergote I, Harter P, Chiva L. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. Cancer 2019;125 Suppl 24:4594-7.
2. Batista TP, Badiglian-Filho L, Baiocchi G. How much “surgical eff ort” should be added to HIPEC? Braz J Oncol 2018;14:1-4.
3. Batista TP. Comment on: surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2017;24:630.
4. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230-40.
5. Koole SN, Kieffer JM, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Eur J Surg Oncol 2019; doi: 10.1016/j.ejso.2019.05.006.
6. Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, et al. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. J Clin Oncol 2019;37:2041-205.
7. Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol 2016;113:796-803.
8. Batista TP, Sarmento BJQ, Loureiro JF, Petruzziello A, Lopes A, et al. A Proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and DMPM. Rev Col Bras Cir 2017;44:530-44.
9. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015;22:1570-5.
10. Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia - a review. Int J Hyperthermia 1997;13:439-57.
11. Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 2013;39:1435-43.
12. Pelz JO, Vetterlein M, Grimmig T, Kerscher AG, Moll E, et al. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol 2013;20:1105-13.
13. Zunino B, Rubio-Patiño C, Villa E, Meynet O, Proics E, et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene 2016;35:261-8.
14. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495-505.
15. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:2391-402.
16. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;381:2403-15.
17. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381:2416-28.
18. Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review. J Ovarian Res 2019;12:103.
19. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
20. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2003;21:3194-200.
21. Armstrong DK, Walker JL. Role of intraperitoneal therapy in the initial management of ovarian cancer. J Clin Oncol 2019;37:2416-9.
22. Riggs MJ, Pandalai PK, Kim J, Dietrich CS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. Diagnostics (Basel) 2020;10:43.
23. Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, et al. Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. Curr Med Chem 2017;24:1586-606.
24. Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study. Br J Cancer 2013;108:1231-7.
25. Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, et al. Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. Gynecol Oncol 2018;151:477-80.
26. Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol 2014;110:661-5.
27. Yarema R, Volodko N, Fetsych T, Оhorchak M, Petronchak O, et al. Cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) in combined treatment of ovarian cancer: time for the beginning of personalized therapy? Curr Issues Pharm Med Sci 2019;32:154-9.
28. Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, et al. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecol Oncol 2019;152:2.
29. Deraco M, Sinukumar S, Salcedo-Hernández RA, Rajendra VJ, Baratti D, et al. Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy. Eur J Surg Oncol 2019;45:2103-8.
30. Somashekar S, Rohit Kumar C, Ashwin K, Zaveri1 S, Ahuja VK, et al. 334 A prospective non-randomized study comparing the outcomes following complete versus selective parietal peritonectomy during CRS+HIPEC for advanced epithelial ovarian cancer. Int J Gynecol Cancer 2019;29:A138.
31. Tate S, Nishikimi K, Kato K, Matsuoka A, Kambe M, et al. Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer. J Gynecol Oncol 2020;31:e34.
32. da Costa AA, Valadares CV, Baiocchi G, Mantoan H, Saito A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol 2015;22 Suppl 3:S971-8.
33. Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, et al. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol Oncol 2020;156:38-44.
34. Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A 2011;108:9851-6.
35. Hegyi G, Szigeti GP, Szász A. Hyperthermia versus oncothermia: cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med 2013;2013:672873.
36. Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, et al. Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA replication arrest. Cancer Res 2016;76:2868-75.
37. Batista TP, Kusamura S. Comments on: pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. J Gynecol Oncol 2019;30:e111.
38. Batista TP, Carneiro VCG, Tancredi R, Teles ALB, Badiglian-Filho L, et al. Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach. Cancer Manag Res 2017;9:869-78.
39. Neuenschwander B, Rouyrre N, Hollaender N, Zuber E, Branson M. A proof of concept phase II non-inferiority criterion. Stat Med 2011;30:1618-27.
40. Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open 2020;3:e1918939.
